Jennison Associates LLC trimmed its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 21.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 410,057 shares of the company's stock after selling 110,333 shares during the quarter. Jennison Associates LLC owned about 1.43% of Krystal Biotech worth $74,643,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors also recently modified their holdings of KRYS. EFG Asset Management North America Corp. increased its stake in Krystal Biotech by 0.5% during the 2nd quarter. EFG Asset Management North America Corp. now owns 12,555 shares of the company's stock valued at $2,308,000 after purchasing an additional 60 shares in the last quarter. GAMMA Investing LLC increased its stake in Krystal Biotech by 160.3% during the 2nd quarter. GAMMA Investing LLC now owns 151 shares of the company's stock valued at $28,000 after purchasing an additional 93 shares in the last quarter. Nisa Investment Advisors LLC increased its stake in Krystal Biotech by 11.1% during the 2nd quarter. Nisa Investment Advisors LLC now owns 940 shares of the company's stock valued at $173,000 after purchasing an additional 94 shares in the last quarter. Arizona State Retirement System boosted its holdings in shares of Krystal Biotech by 2.1% during the 2nd quarter. Arizona State Retirement System now owns 5,147 shares of the company's stock valued at $945,000 after acquiring an additional 108 shares during the last quarter. Finally, Fiera Capital Corp boosted its holdings in shares of Krystal Biotech by 0.8% during the 2nd quarter. Fiera Capital Corp now owns 16,208 shares of the company's stock valued at $2,976,000 after acquiring an additional 130 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors.
Insider Activity
In related news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total value of $4,944,000.00. Following the sale, the insider now owns 1,500,882 shares in the company, valued at approximately $296,814,424.32. The trade was a 1.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 14.10% of the company's stock.
Analyst Ratings Changes
A number of analysts have recently issued reports on KRYS shares. Chardan Capital raised their price target on shares of Krystal Biotech from $153.00 to $208.00 and gave the company a "buy" rating in a report on Monday, August 5th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Krystal Biotech in a report on Thursday, August 29th. Evercore ISI raised their price target on shares of Krystal Biotech from $201.00 to $206.00 and gave the company an "outperform" rating in a report on Monday, August 12th. William Blair raised shares of Krystal Biotech to a "strong-buy" rating in a report on Friday, August 30th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $221.00 price target on shares of Krystal Biotech in a report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $202.29.
Check Out Our Latest Analysis on Krystal Biotech
Krystal Biotech Stock Up 2.4 %
NASDAQ:KRYS traded up $4.19 during trading hours on Thursday, hitting $182.29. 185,178 shares of the stock traded hands, compared to its average volume of 327,009. Krystal Biotech, Inc. has a 1 year low of $99.00 and a 1 year high of $219.34. The company has a market cap of $5.24 billion, a price-to-earnings ratio of 100.62 and a beta of 0.82. The stock has a 50 day moving average price of $180.03 and a 200 day moving average price of $181.99.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.07. The business had revenue of $83.84 million for the quarter, compared to the consensus estimate of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The company's revenue for the quarter was up 879.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.67) earnings per share. Equities analysts forecast that Krystal Biotech, Inc. will post 2.97 earnings per share for the current fiscal year.
Krystal Biotech Company Profile
(
Free Report)
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Further Reading
Before you consider Krystal Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.
While Krystal Biotech currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
